TipRanks
Advertisement
Advertisement

HK:1541 Stock Latest News

ImmuneOnco reshapes board with resignation and proposed appointment of independent director
Company AnnouncementsImmuneOnco reshapes board with resignation and proposed appointment of independent director
1M ago
1541
ImmuneOnco Starts Phase II Trial of Dual-Immunotherapy Combo for Advanced Liver Cancer
PremiumCompany Announcements
ImmuneOnco Starts Phase II Trial of Dual-Immunotherapy Combo for Advanced Liver Cancer
1M ago
1541
ImmuneOnco Advances Lead Leukemia Drug to Fully Enrolled Phase III Trial
PremiumCompany Announcements
ImmuneOnco Advances Lead Leukemia Drug to Fully Enrolled Phase III Trial
1M ago
1541
ImmuneOnco Advances PAH Candidate IMC-003 With First Patient Dosed and Phase I Enrolment Completed
PremiumCompany Announcements
ImmuneOnco Advances PAH Candidate IMC-003 With First Patient Dosed and Phase I Enrolment Completed
1M ago
1541
ImmuneOnco Wins FDA Nod to Test Bispecific IMM0306 in Lupus Trial
PremiumCompany Announcements
ImmuneOnco Wins FDA Nod to Test Bispecific IMM0306 in Lupus Trial
1M ago
1541
ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend
PremiumCompany AnnouncementsImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend
2M ago
1541
ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection
Premium
Company Announcements
ImmuneOnco Boosts Metabolic and Rare Disease Subsidiary with RMB50 Million Capital Injection
2M ago
1541
ImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary
Premium
Company Announcements
ImmuneOnco Details ESOP-Linked Capital Increase at Non-Oncology Subsidiary
2M ago
1541
ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease
PremiumCompany Announcements
ImmuneOnco Starts Phase II/III Trial of First-in-Class IMM0306 for IgG4-Related Disease
3M ago
1541
ImmuneOnco flagged by HKEX over shareholder loan compliance
PremiumCompany Announcements
ImmuneOnco flagged by HKEX over shareholder loan compliance
3M ago
1541
ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection
PremiumCompany Announcements
ImmuneOnco Dilutes Stake in Subsidiary via De Minimis Connected Capital Injection
3M ago
1541
ImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds
PremiumCompany Announcements
ImmuneOnco Deploys HK$87.5 Million Into Vital Ventures Cash Management Funds
3M ago
1541
ImmuneOnco plans on-market H-share buyback to signal confidence and boost value
PremiumCompany AnnouncementsImmuneOnco plans on-market H-share buyback to signal confidence and boost value
4M ago
1541
ImmuneOnco Shareholders Approve All AGM Resolutions and Grant New Capital Mandates
Premium
Company Announcements
ImmuneOnco Shareholders Approve All AGM Resolutions and Grant New Capital Mandates
4M ago
1541
ImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement
Premium
Company Announcements
ImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement
4M ago
1541
ImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus
PremiumCompany Announcements
ImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus
4M ago
1541
ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate
PremiumCompany Announcements
ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate
5M ago
1541
ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
PremiumCompany Announcements
ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
6M ago
1541
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
PremiumCompany Announcements
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
6M ago
1541
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
PremiumCompany AnnouncementsImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
6M ago
1541
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
Premium
Company Announcements
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
7M ago
1541
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
Premium
Company Announcements
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
7M ago
1541

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >